This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Guang Ren, S. Articles by Melmed, S. Search for Related Content PubMed PubMed Citation Articles by Guang Ren, S. Articles by Melmed, S.

Measurement of Leukemia Inhibitory Factor in Biological Fluids by Radioimmunoassay¹

Department of Medicine, Cedars-Sinai Research Institute, University of California School of Medicine, Los Angeles, California 90048

Address all correspondence and requests for reprints to: Dr. Shlomo Melmed, M.D., Division of Endocrinology and Metabolism, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, B-131, Los Angeles, California 90048. E-mail: melmed{at}cshs.org

Abstract

Leukemia inhibitory factor (LIF) exhibits multiple biological activities in various tissues, and we have shown that LIF activates POMC gene transcription in response to immune signals. As higher serum levels of LIF have been reported in septicemia, we measured LIF values in biological fluids by RIA. Immunoreactive LIF was detected in 303 of 428 human serum samples. Circulating LIF detection rates were 69% in acute inflammatory diseases, 83% in chronic inflammatory diseases, 61% in noninflammatory diseases, and 90% in cancer patients. Serum concentrations of human LIF was higher in patients with inflammatory disease than in noninflammatory disease (0.80 ± 0.10 vs. 0.53 ± 0.02 ng/mL; P < 0.05) or in cancer patients (0.44 ± 0.06; P < 0.05). Higher serum human LIF levels were found in septicemia (0.78 ± 0.14 ng/mL), pneumonia (0.80 ± 0.10 ng/mL), acute bronchitis (0.88 ± 0.09 ng/mL), other infections (1.01 ± 0.17 ng/mL), and systemic lupus erythematosus (SLE; 0.79 ± 0.06 ng/mL). In 7 septicemia patients, Gram-negative infection was associated with higher LIF levels (1.06 ± 0.16 ng/mL) than was Gram-positive infection (0.58 ± 0.14 ng/mL). In patients with acute inflammatory disease, serum LIF levels decreased within several days after hospitalization.

To test circulating mouse (m) LIF changes in response to inflammatory stress, lipopolysaccharide (LPS) was injected ip to mice. LPS increased serum mLIF values concordantly with ACTH levels. After ip injection of 80 µg LPS, serum mLIF increased by 144% (P < 0.05), 173% (P < 0.05), and 134% at 30, 90, and 120 min respectively. In vitro, however, LPS did not increase ACTH and mLIF secretion from dispersed mouse primary pituitary cells.

These results suggest that LIF is an important participant in the pathogenesis of the acute inflammatory response. The elevated serum LIF levels observed in inflammation do not appear to originate from the pituitary.

This article has been cited by other articles:

				L. J. Quinton, M. R. Jones, B. E. Robson, B. T. Simms, J. A. Whitsett, and J. P. Mizgerd Alveolar Epithelial STAT3, IL-6 Family Cytokines, and Host Defense during Escherichia coli Pneumonia Am. J. Respir. Cell Mol. Biol., June 1, 2008; 38(6): 699 - 706. [Abstract] [Full Text] [PDF]

				S.-G. Ren and S. Melmed Pyridoxal Phosphate Inhibits Pituitary Cell Proliferation and Hormone Secretion Endocrinology, August 1, 2006; 147(8): 3936 - 3942. [Abstract] [Full Text] [PDF]

				S.-G. Ren, S. Kim, J. Taylor, J. Dong, J.-P. Moreau, M. D. Culler, and S. Melmed Suppression of Rat and Human Growth Hormone and Prolactin Secretion by a Novel Somatostatin/Dopaminergic Chimeric Ligand J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5414 - 5421. [Abstract] [Full Text] [PDF]

				A. Beishuizen and L. G. Thijs Review: Endotoxin and the hypothalamo-pituitary-adrenal (HPA) axis Innate Immunity, February 1, 2003; 9(1): 3 - 24. [Abstract] [PDF]

				A. Ben-Shlomo, I. Miklovsky, S.-G. Ren, W. H. Yong, A. P. Heaney, M. D. Culler, and S. Melmed Leukemia Inhibitory Factor Regulates Prolactin Secretion in Prolactinoma and Lactotroph Cells J. Clin. Endocrinol. Metab., February 1, 2003; 88(2): 858 - 863. [Abstract] [Full Text] [PDF]

				C. J. Auernhammer and S. Melmed Leukemia-Inhibitory Factor--Neuroimmune Modulator of Endocrine Function Endocr. Rev., June 1, 2000; 21(3): 313 - 345. [Abstract] [Full Text]